N/A N=224 Randomized Single-blind Supportive Care

Effects of a Rheumatoid Arthritis Self-management Program

Arthritis, Rheumatoid

Bottom Line

View on ClinicalTrials.gov: NCT03470740 ↗

Enrolled (actual)

224

Serious AEs

—

Results posted

Aug 2019

Primary outcome: Primary: Disease Activity — 3.38; 3.62 score on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: rheumatoid arthritis self-management program (Behavioral)
Age: Adult, Older Adult · 20+ yrs
Sex: All
Sponsor: Chang Gung Memorial Hospital
Primary completion: Jul 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Disease Activity	3.38; 3.62	—
SECONDARY Arthritis Self-efficacy- Pain	35.21; 32.72	—
SECONDARY Arthritis Self-efficacy- Other	51.71; 48.96	—
SECONDARY SF-36 Quality of life_Physical Component Scores	51.29; 48.88	—
SECONDARY Physical Functioning	23.72; 26.14	—
SECONDARY Self-management Behaviors	16.69; 16.24	—
SECONDARY SF-36 Quality of Life_Mental Component Scores (MCS)	50.98; 48.97	—

Summary

Rheumatoid arthritis (RA) is a persistent systemic disease. WHO (World Health Organization) commented that a crucial goal of heath care for RA is prevention of loss of daily function by patients' self-management (SM) skills; however, a comprehensive rheumatoid arthritis self-management (RASm) for RA patients' day-to-day self-managing is limited in Taiwan. Aims: The aims of the study are: (1) to implement the RASm program, (2) to determine the effectiveness of the program with 6 months follow-up, and (3) to understand participants' experiences when receiving the RASm program for the experimental group.

Eligibility Criteria

Inclusion Criteria

Diagnosed with RA
Age of 20 years or over
Disease considered have been stable for at least 3 months
Able to understand and comply with the study treatment

Exclusion Criteria

Suffering from other terminal illnesses, severe dementia or another debilitating psychiatric disorder
Living in a long-term care facility
Participation in another research protocol

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03470740). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.